Device Trial Radar · NCT03028415
AMPLEX Ankle Fusion and Hindfoot
Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jul 28, 2017
Primary completion
Jan 9, 2020
Study completion Jul 9, 2020
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 23, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate that AMPLEX is non-inferior to autogenous bone graft (ABG) for bone fusion in a population indicated for single, double, or triple hindfoot arthrodesis or ankle arthrodesis surgery with supplemental graft material.
Conditions
- Arthrodesis Surgery Involving the Hindfoot or Ankle
Interventions
AMPLEXDevice
A bone graft substitute
Autogenous Bone Graft (ABG)Procedure
Control material administered by surgical implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) EndpointTime frame: At week 52
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Physician Research Group
Gilbert, Arizona
35 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.